Mutual of America Capital Management LLC lessened its holdings in Intersect ENT Inc (NASDAQ:XENT) by 8.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,523 shares of the medical equipment provider’s stock after selling 7,217 shares during the quarter. Mutual of America Capital Management LLC owned about 0.28% of Intersect ENT worth $2,674,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of XENT. Jennison Associates LLC lifted its holdings in shares of Intersect ENT by 22.4% in the 4th quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock worth $65,973,000 after acquiring an additional 372,320 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Intersect ENT by 39.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 160,883 shares of the medical equipment provider’s stock valued at $5,213,000 after buying an additional 45,444 shares in the last quarter. Bank of Montreal Can bought a new stake in Intersect ENT during the 4th quarter valued at about $135,000. Simplex Trading LLC bought a new stake in Intersect ENT during the 4th quarter valued at about $242,000. Finally, GSA Capital Partners LLP bought a new stake in Intersect ENT during the 3rd quarter valued at about $926,000. 87.44% of the stock is owned by institutional investors and hedge funds.
Intersect ENT Inc (XENT) traded down $0.10 on Friday, hitting $37.70. 153,127 shares of the company traded hands, compared to its average volume of 295,461. Intersect ENT Inc has a 1 year low of $12.50 and a 1 year high of $38.30. The firm has a market cap of $1,110.49, a PE ratio of -59.84 and a beta of 0.79.
Several equities research analysts have recently commented on XENT shares. Zacks Investment Research downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Northland Securities reissued a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a research report on Friday, November 3rd. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research report on Tuesday, November 7th. BidaskClub downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a research report on Monday, December 11th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.38.
TRADEMARK VIOLATION NOTICE: “Intersect ENT Inc (XENT) Shares Sold by Mutual of America Capital Management LLC” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://weekherald.com/2018/02/18/intersect-ent-inc-xent-shares-sold-by-mutual-of-america-capital-management-llc.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.